Available as Ozempic (for type 2 diabetes), Wegovy (for weight management), and Rybelsus (oral tablet for diabetes), semaglutide targets the GLP-1 receptor exclusively
Sabina Hemmi, the cofounder and chief executive of the GLP-1 provider comparison startup GLP Winner, says she no longer even attempts to track new startups, because there are simply too many
2023), whereas cognitive advantages shown in diabetic individuals indicate a possible preventive effect against Alzheimer's in high-risk groups (Athauda et al
These numbers exceed what semaglutide produces over its entire 68-week treatment period
Wegovy, as an injection, is FDA approved to: Reduce excess body weight and maintain long-term weight reduction in: Adults with obesity and adolescents ages 12 years and older with obesity Adults with overweight plus at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol Treat a serious type of fatty liver disease called noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring (stage F2 to F3 fibrosis) Lower the risk of major cardiovascular problems (such as heart attack, stroke, and heart-related death) in adults with established cardiovascular disease and obesity or overweight Contrave is FDA approved to: Reduce excess body weight and maintain long-term weight reduction in: Adults with obesity, defined as a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher (overweight) plus at least one weight-related medical condition To recap, heres an at-a-glance comparison of FDA-approved uses for Wegovy vs
However, this proves to be more complex and requires careful dose adjustment
